following a full submission assessed under the end of life and ultra orphan processes
blinatumomab (Blincyto®) is accepted for use within NHS Scotland.
Indication under review: The treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).
In a non-comparative phase II study of patients with relapsed or refractory Philadelphia chromosome-negative B-precursor ALL, blinatumomab was associated with clinically relevant complete remission rates. Controlled data with clinical outcomes are currently lacking.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of blinatumomab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice238KB (PDF)
- Medicine name:
- blinatumomab (Blincyto)
- SMC ID:
- the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 13 June 2016